Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ATYR vs ADPT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ATYR Captures Overall Composite Edge (34.3 SELL vs 43.2 HOLD), While ADPT Leads 4–2 on Growth & Valuation Pillars
ATYR Overall Winner
6-Pillar Tally: ATYR 2 – 4 ADPT
Matrix Metrics: ATYR 3 – 5 ADPT
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Adaptive Biotechnologies Corporation (ADPT) on higher Unified Composite conviction (34.3/100 SELL vs. 43.2/100 HOLD) after splitting the core matrix 3–5 (led by Growth & Scale, Profitability & Quality), while ADPT wins 4–2 across the 6-pillar growth and valuation breakdown. ATYR trades at $4.83 (N/M Forward P/E, 0.0% operating margin) versus ADPT at $28.46 (N/M Forward P/E, -16.2% operating margin).
- Composite vs. Pillar Nuance: While ADPT currently prints a higher short-term Unified Composite Score (43.2/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -16.2% operating margin) and revenue trajectory (+0.0% vs. -10.7% YoY).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ATYR vs ADPT
ATYR
Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
$4.83
-7.82% 1D
Market Cap
$15.6M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
-9.57β · 13806% Vol
Unified Composite Score
34.3
SELL
Tech 50.0
Fund 36.0
Flow 69.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
ADPT
Adaptive Biotechnologies Corporation Common Stock
$28.46
+2.12% 1D
Market Cap
$4.7B
TTM Revenue
$298M
Forward P/E
N/M
Beta / 30D Vol
1.71β · 59% Vol
Unified Composite Score
43.2
HOLD
Tech 15.0
Fund 42.0
Flow 68.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (ATYR 2 – 4 ADPT)
1. Valuation Multiples
ADPT
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
16.9x
2. Growth & Scale
ATYR
Revenue Growth (YoY)
+0.0%
-10.7%
Earnings Growth (YoY)
+0.0%
-70.1%
TTM Revenue (USD)
N/A
$298M
Market Cap
$15.6M
$4.7B
3. Profitability & Quality
ATYR
Gross Margin
N/A
46.2%
Operating Margin
0.0%
-16.2%
Net Profit Margin
0.0%
-23.7%
Return on Equity (ROE)
-93.7%
-36.4%
4. Balance Sheet & Cash Flow
ADPT
Cash Generation (TTM)
N/A
-$8.8M
Cash Flow Margin
N/A
-3.0%
Net Cash / Leverage
$4.9M Net Cash
$333M Net Debt (2.32x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ADPT
Options Structure Phase
UNCLASSIFIED
BREAKOUT
Current IV / %ile
154.5% (36th %ile)
78.0% (36th %ile)
Put/Call OI Skew
N/A
0.01x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markup
ACCUMULATION · Markup
6. R&D & Supply-Chain Moat
ADPT
OpEx & R&D Intensity
N/A
62.4% of Rev ($186M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Diagnostics & Research Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ATYR (3) vs ADPT (5)| Institutional Metric | ATYR | ADPT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $15.6M | $4.7B | ADPT | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +0.0% | -10.7% | ATYR | |
| Operating Margin (TTM) | 0.0% | -16.2% | ATYR | |
| Net Profit Margin | 0.0% | -23.7% | ATYR | |
| Return on Equity (ROE) | -93.7% | -36.4% | ADPT | |
| 52-Week Range Position | 60% ($0–$8) | 81% ($12–$32) | ADPT | |
| Beta / 30D Volatility | -9.57β · 13806% Vol | 1.71β · 59% Vol | ADPT | |
| Unified Institutional Score | 34.3 / 100 (SELL) | 43.2 / 100 (HOLD) | ADPT | |
| Trailing 12M Revenue (USD) | N/A | $298M | Scale | |
| Gross Profit Margin (TTM) | N/A | 46.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 16.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | N/A ($4.9M Net Cash) | -$8.8M ($333M Net Debt (2.32x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ATYR +2694.22 pp
3M Horizon
ATYR +794.88 pp
6M Horizon
ATYR +780.4 pp
1Y Horizon
ATYR +439.59 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ATYR Revenue | ADPT Revenue | ATYR Op. Margin | ADPT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $60M | N/A | -89.4% | ADPT |
| FY2019 | $0M | $90M | -5445.0% | -92.1% | ADPT |
| FY2020 | $10M | $100M | -152.2% | -155.3% | ATYR |
| FY2021 | N/A | $150M | N/A | -135.4% | ADPT |
| FY2022 | $10M | $190M | -446.8% | -108.0% | ADPT |
| FY2023 | $0M | $170M | -15557.8% | -133.3% | ADPT |
| FY2024 | $0M | $180M | -28899.6% | -90.8% | ADPT |
| FY2025 | $0M | $280M | -40856.3% | -20.6% | ADPT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ATYR
UNCLASSIFIED
Current IV
154.5%
IV Percentile
36th %ile
Put/Call OI Skew
N/A
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ADPT
BREAKOUT
Current IV
78.0%
IV Percentile
36th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact ADPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ATYR Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ADPT Moat Profile
Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
OpEx & R&D Reinvestment
62.4% of Rev ($186M)
90D Engineering Disclosures
0 Published
Investor FAQ ATYR vs ADPT Key Questions & Quantitative Answers
As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over Adaptive Biotechnologies Corporation (ADPT) on higher Unified Composite conviction (34.3/100 SELL vs. 43.2/100 HOLD) after splitting the core matrix 3–5 (led by Growth & Scale, Profitability & Quality), while ADPT wins 4–2 across the 6-pillar growth and valuation breakdown. ATYR trades at $4.83 (N/M Forward P/E, 0.0% operating margin) versus ADPT at $28.46 (N/M Forward P/E, -16.2% operating margin). Composite vs. Pillar Nuance: While ADPT currently prints a higher short-term Unified Composite Score (43.2/100 HOLD vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -16.2% operating margin) and revenue trajectory (+0.0% vs. -10.7% YoY).
ATYR leads the Growth & Scale pillar: ATYR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ADPT at -10.7% YoY revenue growth and -70.1% YoY earnings growth on $298M TTM revenue (46.2% gross margin, -16.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ATYR cumulative revenue shifted +0.0% while ADPT shifted +366.7%. In operating R&D and SG&A reinvestment, ATYR deploys N/A (0 90-day corporate R&D disclosures) versus 62.4% of Rev ($186M) (0 disclosures) for ADPT.
ADPT screens cheaper on headline valuation multiples. ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ADPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.9x EV/Revenue (-3.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATYR (-93.7% ROE) versus ADPT (-36.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.57β · 13806% Vol realized risk). By comparison, ADPT carries 78.0% implied volatility (36th %ile, Balanced (25th–60th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.71β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ADPT vs ATYR · Reverse Pair
ATYR vs LRMR
· Sector Peer
ATYR vs RZLT
· Sector Peer
ADPT vs BEAM
· Sector Peer
ADPT vs TXG
· Sector Peer
ADPT vs TWST
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem